- Email: [email protected]
Cbdca for Refractory or Relapsed Aggressive B-Cell Lymphoma
Annals of Oncology 25 (Supplement 5): v44–v74, 2014 doi:10.1093/annonc/mdu435.63
Oral Session (Oral presentations categorized by each organ) O2
1
5
Takuro Matsumoto, Nobuhiko Nakamura, Yuhei Shibata, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Takeshi Hara, Hisashi Tsurumi, Hisataka Moriwaki First Department of Internal Medicine, Gifu University
abstracts
Background: We previously reported the efficacy of salvage chemotherapy with P-IMVP-16/CBDCA consisting of methylprednisolone (mPSL), carboplatin (CBDCA), etoposide (VP-16), ifosfamide (IFM), and methotrexate (MTX) for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP (Eur J Haematol 2002). The purpose of this study was to determine the efficacy and safety of
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v59/2240293 by guest on 24 October 2019
EFFICACY AND SAFETY OF RITUXIMAB COMBINED WITH P-IMVP-16/CBDCA FOR REFRACTORY OR RELAPSED AGGRESSIVE B-CELL LYMPHOMA
salvage chemotherapy with rituximab (R) combined with P-IMVP-16/CBDCA (R-P-IMVP-16/CBDCA) for refractory or relapsed aggressive B-cell lymphoma. Methods: We retrospectively analyzed 32 patients with relapsed or refractory aggressive B-cell lymphoma who had received R-P-IMVP-16/CBDCA (R: 375mg/m2 on day1, mPSL: 1000mg/body on days 2-4, IFM: 1000mg/m2 on days 2-6, MTX: 30mg/m2 on day 4 and 11, VP-16: 80mg/m2 on days 2-4, and CBDCA 300mg/m2 on day 2, with granulocyte colony-stimulating factor every 21 days) between June 2004 and June 2013. Patients aged 70 or older were given 75% of the standard dose. All patients received R-CHOP or R-THP-COP regimen as a first-line chemotherapy. The overall response rate (ORR), survival, and toxicity were analyzed. Results: The pathology of underlying lymphoma comprised diffuse large-B cell lymphoma (n = 26), follicular lymphoma grade 3 (n = 3), intravascular large B-cell lymphoma (n = 1) and mantle cell lymphoma (n = 1). ORR was 53.1% (17 pts), including 28.1% (9 pts) CR. Median overall survival (OS) and progression-free survival were 19.1 months and 3.5 months, respectively. Nine patients (28.1%) proceeded to autologous stem cell transplantation and their 2-year OS was 87.5%. Although the major toxicity was neutropenia, no patient died of infection related to neutropenia. Non-hematological adverse effects were predominantly mild and tolerable. Conclusions: R-P-IMVP-16/CBDCA chemotherapy for patients with refractory or relapsed aggressive B-cell lymphoma might be effective as a salvage therapy.
Oral Session (Oral presentations categorized by each organ) O2
1
5
Takuro Matsumoto, Nobuhiko Nakamura, Yuhei Shibata, Hiroshi Nakamura, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Takeshi Hara, Hisashi Tsurumi, Hisataka Moriwaki First Department of Internal Medicine, Gifu University
abstracts
Background: We previously reported the efficacy of salvage chemotherapy with P-IMVP-16/CBDCA consisting of methylprednisolone (mPSL), carboplatin (CBDCA), etoposide (VP-16), ifosfamide (IFM), and methotrexate (MTX) for patients with aggressive non-Hodgkin’s lymphoma who had previously received CHOP (Eur J Haematol 2002). The purpose of this study was to determine the efficacy and safety of
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v59/2240293 by guest on 24 October 2019
EFFICACY AND SAFETY OF RITUXIMAB COMBINED WITH P-IMVP-16/CBDCA FOR REFRACTORY OR RELAPSED AGGRESSIVE B-CELL LYMPHOMA
salvage chemotherapy with rituximab (R) combined with P-IMVP-16/CBDCA (R-P-IMVP-16/CBDCA) for refractory or relapsed aggressive B-cell lymphoma. Methods: We retrospectively analyzed 32 patients with relapsed or refractory aggressive B-cell lymphoma who had received R-P-IMVP-16/CBDCA (R: 375mg/m2 on day1, mPSL: 1000mg/body on days 2-4, IFM: 1000mg/m2 on days 2-6, MTX: 30mg/m2 on day 4 and 11, VP-16: 80mg/m2 on days 2-4, and CBDCA 300mg/m2 on day 2, with granulocyte colony-stimulating factor every 21 days) between June 2004 and June 2013. Patients aged 70 or older were given 75% of the standard dose. All patients received R-CHOP or R-THP-COP regimen as a first-line chemotherapy. The overall response rate (ORR), survival, and toxicity were analyzed. Results: The pathology of underlying lymphoma comprised diffuse large-B cell lymphoma (n = 26), follicular lymphoma grade 3 (n = 3), intravascular large B-cell lymphoma (n = 1) and mantle cell lymphoma (n = 1). ORR was 53.1% (17 pts), including 28.1% (9 pts) CR. Median overall survival (OS) and progression-free survival were 19.1 months and 3.5 months, respectively. Nine patients (28.1%) proceeded to autologous stem cell transplantation and their 2-year OS was 87.5%. Although the major toxicity was neutropenia, no patient died of infection related to neutropenia. Non-hematological adverse effects were predominantly mild and tolerable. Conclusions: R-P-IMVP-16/CBDCA chemotherapy for patients with refractory or relapsed aggressive B-cell lymphoma might be effective as a salvage therapy.